Great BD Opportunity Available!
Major Chinese pharmaceutical companies are sourcing innovative therapeutic assets across three therapeutic areas: Oncology (solid tumors and hematological malignancies), autoimmune diseases, and neurology (covering both CNS and PNS, including neurological and psychiatric indications).
We only consider candidates at Phase 1 or later clinical stages. Cell and gene therapy (CGT) assets are excluded; all other modalities are acceptable. Preference will be given to assets with exclusive Mainland China rights encompassing research & development, manufacturing, and commercialization.
Pharmaceutical companies with relevant programs are welcome to contact the DrugTimes BD team promptly!
Email: BD@drugtimes.cn
Thank you very much.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
